Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a surgical procedure called ERBT (a type of tumour removal) and whose final pathology results showed stage pT1 disease (an early stage of tumour growth) with clear margins, meaning no cancer cells were found at the edges of the removed tissue in any direction.
Who may not be able to join:
- People whose tumour was too large to be treated with the ERBT procedure.
- People who have remaining tumour tissue still present after their procedure.
- People who have tumours in more than 4 separate locations.
- People who have a type of cancer called CIS (carcinoma in situ), which refers to abnormal cells that have not yet spread beyond their original layer.
- People whose pathology results after their initial removal procedure showed cancer cells at the edges of the removed tissue in any direction.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mahmoud Laymon, MD,MRCS, Urology &Nephrology Center, Mansoura University, Egypt
Phone: 01002275698
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impact of avoiding repeat resection on recurrence and progression free survival.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.